RGLS: Regulus Therapeutics Inc. Stock

by  •  • Comments Off on RGLS: Regulus Therapeutics Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 545.22
Enterprise Value ($M) 506.70
Book Value ($M) 69.03
Book Value / Share 1.10
Price / Book 7.14
NCAV ($M) 74.57
NCAV / Share 1.08
Price / NCAV 7.31

Profitability (mra)
Return on Invested Capital (ROIC) -0.61
Return on Assets (ROA) -0.42
Return on Equity (ROE) -0.44

Liquidity (mrq)
Quick Ratio 10.52
Current Ratio 10.98

Balance Sheet (mrq) ($M)
Current Assets 71.69
Assets 74.83
Liabilities 5.80
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -50.04
Net Income -46.36
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -41.67
Cash from Investing -35.98
Cash from Financing 92.42

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-08 13G Point72 Asset Management, L.P. 5.90 62.71
11-14 13G/A Ra Capital Management, L.p. 1.20 -87.73
11-14 13G/A Biotechnology Value Fund L P 1.30 -90.85
11-14 13G/A DAFNA Capital Management LLC 1.37 -19.43
11-12 13G/A Vanguard Group Inc 6.24 0.00
11-08 13G BlackRock, Inc. 6.20 0.00
10-11 13G Octagon Capital Advisors LP 6.50
2024-04-10 13G/A Fmr Llc 4.46 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2025-04-30 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 or ☐ T
2025-03-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-09 267,182 1,530,330 17.46
2025-05-08 131,256 615,066 21.34
2025-05-07 165,094 911,776 18.11
2025-05-06 130,327 871,067 14.96

(click for more detail)

Similar Companies
RENB – Renovaro Inc. REVB – Revelation Biosciences, Inc.
RGC – Regencell Bioscience Holdings Limited RMTI – Rockwell Medical, Inc.
RNAZ – TransCode Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Regulus Therapeutics